RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update
10/16/2020 - 07:00 AM
NEW YORK , Oct. 16, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it will report its audited financial results for the full year ended June 30, 2020 on Tuesday, October 27 2020 .
Analyst conference call The Company will hold an analyst conference call at 8:30 a.m. (EDT) / 12:30 p.m. (GMT) p.m. on Tuesday, October 27 2020 . James McCullough , CEO and O. James Sterling , CFO will discuss the full year financial results and provide a corporate update.
Conference Call Details US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551 US/Canada Participant International Dial-In Number: (914) 987-7290 United Kingdom Participant Dial-In Number: 080 0028 8438United Kingdom , London Participant Dial-In Number: 020 3107 0289
Conference ID: 7673467
Webcast Registration link: https://edge.media-server.com/mmc/p/6gfpkm3j
UK Retail Investor presentation RenalytixAI will be hosting a live online presentation open to all investors at 12.30 p.m. (EDT) / 4.30 p.m. (GMT) on Tuesday , October 27 2020. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business, which will be provided by both James McCullough , CEO and O. James Sterling , CFO.
The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet RenalytixAI plc via the following link:https://www.investormeetcompany.com/renalytix-ai-plc/register-investor
For those investors who have already registered and added to meet the Company, they will automatically be invited.
About Kidney Disease Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant. * https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com .
View original content to download multimedia:http://www.prnewswire.com/news-releases/renalytixai-to-announce-financial-results-for-full-year-ended-june-30-2020-and-provide-corporate-update-301153816.html
SOURCE RenalytixAI
RNLX Rankings
#4481 Ranked by Stock Gains
RNLX Stock Data
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Tags
Technology Services, Packaged Software, Health Care and Social Assistance, Diagnostic Imaging Centers
Country
United Kingdom
City
Penarth
About RNLX
renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev